Does tumour dormancy offer a therapeutic target?

PE Goss, AF Chambers - Nature Reviews Cancer, 2010 - nature.com
PE Goss, AF Chambers
Nature Reviews Cancer, 2010nature.com
The increasing number of cancer survivors is cause for celebration, but this expanding
population has highlighted the problem of tumour dormancy, which can lead to relapse. As
we start to understand more about the biology of dormant cancer cells, we can begin to
address how best to treat this form of disease. Preclinical models and initial clinical trials, as
exemplified in patients with breast cancer, are paving the way to address how best to treat
long-term cancer survivors to minimize the risk of cancer recurrence.
Abstract
The increasing number of cancer survivors is cause for celebration, but this expanding population has highlighted the problem of tumour dormancy, which can lead to relapse. As we start to understand more about the biology of dormant cancer cells, we can begin to address how best to treat this form of disease. Preclinical models and initial clinical trials, as exemplified in patients with breast cancer, are paving the way to address how best to treat long-term cancer survivors to minimize the risk of cancer recurrence.
nature.com